Condition: Gastric Cancer · Sponsor: Cancer Hospital Chinese Academy of Medical Science, Shenzhen Center
In this study, the combination of Adebrelimab (PD-L1 monoclonal antibody) on the basis of standard treatment (two-drug chemotherapy regimen of fluorouracil and platinum drugs) may enhance the immune response in order to enhance the killing effect on tumor cells and bring survival benefits to patients with advanced or metastatic gastric cancer or gastroesophageal junction adenocarcinoma.
This description comes directly from the study's public registry record.
yin wang · 19925153518 · Drwangsz@yeah.net
Always discuss trial participation with your own doctor first.
| Shenzhen Hospital, Cancer Hospital, Chinese Academy of Medical Sciences | Shenzhen, Guangdong, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06776770